• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RIDAFOROLIMUS Drug Record

  • Summary
  • Interactions
  • Claims
  • RIDAFOROLIMUS chembl:CHEMBL2103839 Antineoplastic

    Alternate Names:

    DEFOROLIMUS
    RIDAFOROLIMUS
    MK-8669
    AP 23573
    AP-23573
    42-(DIMETHYLPHOSPHINATE)RAPAMYCIN
    AP23573
    chemidplus:572924-54-0
    chembl:CHEMBL2103839
    pubchem.compound:11520894
    drugbank:06233

    Drug Info:

    Notes rapalogue
    Drug Class Kinase Inhibitors
    FDA Approval not approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    (4 More Sources)

    Publications:

    Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
    Gupta et al., 2015, A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies., Clin. Cancer Res.
  • RIDAFOROLIMUS   MTOR

    Interaction Score: 0.97

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor
    Trial Name Ridaforolimus

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

  • RIDAFOROLIMUS   KRAS

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ridaforolimus + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • RIDAFOROLIMUS   PIK3CA

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ridaforolimus + MK2206
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    26187616


    Sources:
    JAX-CKB

  • MyCancerGenome: RIDAFOROLIMUS

    • Version: 20-Jun-2017

    Alternate Names:
    AP23573 Development Name
    MK8669 Development Name
    RIDAFOROLIMUS Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors
    Notes rapalogue

    Publications:

  • TdgClinicalTrial: RIDAFOROLIMUS

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Ridaforolimus

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
    Gupta et al., 2015, A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies., Clin. Cancer Res.

  • TTD: Ridaforolimus

    • Version: 2020.06.01

    Alternate Names:
    D0O3CV TTD Drug ID

    Drug Info:

    Publications:

  • TALC: RIDAFOROLIMUS

    • Version: 12-May-2016

    Alternate Names:
    RIDAFOROLIMUS Primary Drug Name
    RIDAFOROLIMUS Drug Generic Name
    TALTORVIC Drug Trade Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2103839

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL2103839

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: DEFOROLIMUS

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21